5-Lipoxygenase: Regulation and possible involvement in atherosclerosis

Prostaglandins and Other Lipid Mediators

Volumn 83, Issue 3 SPEC. ISS., 2007, Pages 162-174

  Rådmark, Olof ^a   Samuelsson, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arachidonic acid; Eicosanoid; Inflammation; Leukotriene

Indexed keywords

1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; 1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; CHEMOATTRACTANT; CP 105690; DG 031; ENZYME INHIBITOR; LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CELL MEMBRANE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PROTEIN DOMAIN; REVIEW;

EID: 34247548667     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.01.003     Document Type: Review

References (119)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
2. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8 (2002) 1211-1217
3. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1876-1890
4. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat Struct Biol 1997;4:1003-9 [published erratum appears in Nat Struct Biol 1998;5(3):242].
5. Peters-Golden M., and Brock T.G. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett 487 (2001) 323-326
6. Bach M.K., and Brashler J.R. In vivo and in vitro production of a slow reacting substance in the rat upon treatment with calcium ionophores. J Immunol 113 (1974) 2040-2044
7. Borgeat P., and Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci USA 76 (1979) 2148-2152
8. Jakschik B.A., Sun F.F., Lee L., and Steinhoff M.M. Calcium stimulation of a novel lipoxygenase. Biochem Biophys Res Commun 95 (1980) 103-110
9. Aharony D., and Stein R.L. Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J Biol Chem 261 (1986) 11512-11519
10. Rouzer C.A., and Samuelsson B. On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc Natl Acad Sci USA 82 (1985) 6040-6044
11. Shimizu T., Izumi T., Seyama Y., Tadokoro K., Rådmark O., and Samuelsson B. Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci USA 83 (1986) 4175-4179
12. Skorey K.I., and Gresser M.J. Calcium is not required for 5-lipoxygenase activity at high phosphatidyl choline vesicle concentrations. Biochemistry 37 (1998) 8027-8034
13. 2+ activates 5-lipoxygenase in vitro: dependency on concentrations of phosphatidylcholine and arachidonic acid. Biochemistry 39 (2000) 1840-1848
14. 2 and inhibition by metal ions. Eur J Biochem 210 (1992) 109-117
15. Noguchi M., Miyano M., Matsumoto T., and Noma M. Human 5-lipoxygenase associates with phosphatidylcholine liposomes and modulates LTA(4) synthetase activity. Bba-Lipid Lipid Metab 1215 (1994) 300-306
16. Hammarberg T., Provost P., Persson B., and Rådmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J Biol Chem 275 (2000) 38787-38793
17. Hammarberg T., and Rådmark O. 5-Lipoxygenase binds calcium. Biochemistry 38 (1999) 4441-4447
18. Kulkarni S., Das S., Funk C.D., Murray D., and Cho W. Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J Biol Chem 277 (2002) 13167-13174
19. Schatz-Munding M., Hatzelmann A., and Ullrich V. The involvement of extracellular calcium in the formation of 5-lipoxygenase metabolites by human polymorphonuclear leukocytes. Eur J Biochem 197 (1991) 487-493
20. 2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1. J Biol Chem 278 (2003) 42846-42853
21. Sailer E.R., Schweizer S., Boden S.E., Ammon H.P.T., and Safayhi H. Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 256 (1998) 364-368
22. Nalefski E.A., and Falke J.J. The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci 5 (1996) 2375-2390 [Review] [139 refs]
23. 2+-binding domain. J Biol Chem 273 (1998) 15879-15882
24. Rouzer C.A., Shimizu T., and Samuelsson B. On the nature of the 5-lipoxygenase reaction in human leukocytes: characterization of a membrane-associated stimulatory factor. Proc Natl Acad Sci USA 82 (1985) 7505-7509
25. Goetze A.M., Fayer L., Bouska J., Bornemeier D., and Carter G.W. Purification of a mammalian 5-lipoxygenase from rat basophilic leukemia cells. Prostaglandins 29 (1985) 689-701
26. Hogaboom G.K., Cook M., Newton J.F., et al. Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. Mol Pharmacol 30 (1986) 510-519
27. 2+ levels and phosphatidylcholine vesicles. Biochim Biophys Acta 960 (1988) 261-267
28. Riendeau D., Falgueyret J.P., Meisner D., Sherman M.M., Laliberte F., and Street I.P. Interfacial catalysis and production of a high ratio of leukotriene-A(4) to 5-HPETE by 5-lipoxygenase in a coupled assay with phospholipase-A(2). J Lipid Mediator 6 (1993) 23-30
29. Noguchi M., Miyano M., Kuhara S., Matsumoto T., and Noma M. Interfacial kinetic reaction of human 5-lipoxygenase. Eur J Biochem 222 (1994) 285-292
30. Chen X.S., and Funk C.D. The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem 276 (2001) 811-818
31. Pande A.H., Moe D., Nemec K.N., Qin S., Tan S., and Tatulian S.A. Modulation of human 5-lipoxygenase activity by membrane lipids. Biochemistry 43 (2004) 14653-14666
32. Pande A.H., Qin S., and Tatulian S.A. Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5-lipoxygenase. Biophys J 88 (2005) 4084-4094
33. Qiu Z.H., Gijon M.A., deCarvalho M.S., Spencer D.M., and Leslie C.C. The role of calcium and phosphorylation of cytosolic phospholipase A(2) in regulating arachidonic acid release in macrophages. J Biol Chem 273 (1998) 8203-8211
34. Gijon M.A., Spencer D.M., Kaiser A.L., and Leslie C.C. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol 145 (1999) 1219-1232
35. Walther M., Anton M., Wiedmann M., Fletterick R., and Kuhn H. The N-terminal domain of the reticulocyte-type 15-lipoxygenase is not essential for enzymatic activity but contains determinants for membrane binding. J Biol Chem 277 (2002) 27360-27366
36. Hornig C., Albert D., Fischer L., et al. 1-Oleoyl-2-acetylglycerol stimulates 5-lipoxygenase activity via a putative (phospho)lipid-binding site within the N-terminal C2-like domain. J Biol Chem 280 (2005) 26913-26921
37. Werz O., Klemm J., Samuelsson B., and Rådmark O. 5-Lipoxygenase is phosphorylated by p38 kinase dependent MAPKAP kinases. Proc Natl Acad Sci 97 (2000) 5261-5266
38. Werz O., Bürkert E., Fischer L., et al. Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J 16 (2002) 1441-1443
39. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., and Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279 (2004) 41512-41520 [Epub July 26, 2004]
40. Peters-Golden M., McNish R.W., Sporn P.H., and Balazovich K. Basal activation of protein kinase C in rat alveolar macrophages: implications for arachidonate metabolism. Am J Physiol 261 (1991) L462-L471
41. Lepley R.A., Muskardin D.T., and Fitzpatrick F.A. Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. J Biol Chem 271 (1996) 6179-6184
42. Lepley R.A., and Fitzpatrick F.A. Inhibition of mitogen-activated protein kinase kinase blocks activation and redistribution of 5-lipoxygenase in HL-60 cells. Arch Biochem Biophys 331 (1996) 141-144
43. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47 (2000) 185-201
44. Werz O., Klemm J., Rådmark O., and Samuelsson B. p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. J Leuk Biol 70 (2001) 830-838
45. Werz O., Szellas D., Steinhilber D., and Rådmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 277 (2002) 14793-14800
46. Werz O., Bürkert E., Samuelsson B., Rådmark O., and Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99 (2002) 1044-1052
47. Bürkert E., Rådmark O., Samuelsson B., Steinhilber D., and Werz O. Hypertonicity suppresses ionophore-induced product formation and translocation of 5-lipoxygenase in human leukocytes. J Leukoc Biol 71 (2002) 477-486
48. Bürkert E., Szellas D., Rådmark O., Steinhilber D., and Werz O. Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J Leuk Biol 73 (2003) 191-200
49. Fischer L., Szellas D., Rådmark O., Steinhilber D., and Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 28 (2003) 28
50. Werz O., Klemm J., Samuelsson B., and Rådmark O. Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 97 (2001) 2487-2495
51. Flamand N., Surette M.E., Picard S., Bourgoin S., and Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 62 (2002) 250-256
52. Surette M.E., Krump E., Picard S., and Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol Pharmacol 56 (1999) 1055-1062
53. Boden S.E., Bertsche T., Ammon H.P., and Safayhi H. MEK-1/2 inhibition prevents 5-lipoxygenase translocation in N-formylpeptide-challenged human neutrophils. Int J Biochem Cell Biol 32 (2000) 1069-1074
54. Luo M., Jones S.M., Peters-Golden M., and Brock T.G. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc Natl Acad Sci USA 6 (2003) 6
55. Luo M., Jones S.M., Flamand N., Aronoff D.M., Peters-Golden M., and Brock T.G. Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem 280 (2005) 40609-40616
56. Kooman W.J., Orange R.P., and Austen K.F. J Immunol 105 (1970) 1096-1102
57. Ham E.A., Soderman D.D., Zanetti M.E., Dougherty H.W., McCauley E., and Kuehl F.A. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci USA 80 (1983) 4349-4353
58. Flamand N., Lefebvre J., Surette M.E., Picard S., and Borgeat P. Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J Biol Chem 281 (2006) 129-136
59. Rouzer C.A., Ford H.A., Morton H.E., and Gillard J.W. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 265 (1990) 1436-1442
60. Miller D.K., Gillard J.W., Vickers P.J., et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 (1990) 278-281
61. Dixon R.A., Diehl R.E., Opas E., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
62. Petersgolden M., and Mcnish R.W. Redistribution of 5-lipoxygenase and cytosolic phospholipase-A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun 196 (1993) 147-153
63. Woods J.W., Evans J.F., Ethier D., et al. 5-Lipoxygenase and 5-lipoxygenase activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178 (1993) 1935-1946
64. Woods J.W., Coffey M.J., Brock T.G., Singer I.I., and Petersgolden M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J Clin Invest 95 (1995) 2035-2046
65. Brock T.G., Mcnish R.W., and Petersgolden M. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. J Biol Chem 270 (1995) 21652-21658
66. Pouliot M., Mcdonald P.P., Krump E., et al. Colocalization of cytosolic phospholipase A(2), 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils. Eur J Biochem 238 (1996) 250-258
67. Coffey M., Petersgolden M., Fantone J.C., and Sporn P.H.S. Membrane association of active 5-lipoxygenase in resting cells-evidence for novel regulation of the enzyme in the rat alveolar macrophage. J Biol Chem 267 (1992) 570-576
68. Kargman S., Vickers P.J., and Evans J.F. A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells. J Cell Biol 119 (1992) 1701-1709
69. Hatzelmann A., Fruchtmann R., Mohrs K.H., Raddatz S., and Mullerpeddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X-1005 ((R)-2-<4-(quinolin-2-yl-methoxy)phenyl>-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol 45 (1993) 101-111
70. Brock T.G., McNish R.W., and Peters G.M. Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages. Biochem J 329 (1998) 519-525
71. Mancini J.A., Abramovitz M., Cox M.E., et al. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 318 (1993) 277-281
72. Hatzelmann A., Goossens J., Fruchtmann R., Mohrs K.H., Raddatz S., and Mullerpeddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system-implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol 47 (1994) 2259-2268
73. Charleson S., Evans J.F., Leger S., et al. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur J Pharmacol-Mol Pharm 267 (1994) 275-280
74. Abramovitz M., Wong E., Cox M.E., Richardson C.D., Li C., and Vickers P.J. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 215 (1993) 105-111
75. Mancini J.A., Waterman H., and Riendeau D. Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. J Biol Chem 273 (1998) 32842-32847
76. Plante H., Picard S., Mancini J., and Borgeat P. 5-Lipoxygenase activating protein homodimer in human neutrophils. Evidence for a role in leukotriene synthesis. Biochem J 393 (2006) 211-218
77. Brock T.G., Paine R., and Petersgolden M. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J Biol Chem 269 (1994) 22059-22066
78. Brock T.G., McNish R.W., Bailie M.B., and Peters G.M. Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence. J Biol Chem 272 (1997) 8276-8280
79. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
80. Luo M., Pang C.W., Gerken A.E., and Brock T.G. Multiple nuclear localization sequences allow modulation of 5-lipoxygenase nuclear import. Traffic 5 (2004) 847-854
81. Chen X.S., Zhang Y.Y., and Funk C.D. Determinants of 5-lipoxygenase nuclear localization using green fluorescent protein 5-lipoxygenase fusion proteins. J Biol Chem 273 (1998) 31237-31244
82. Healy A.M., Peters-Golden M., Ping Yao J., and Brock T.G. Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase. J Biol Chem 274 (1999) 29812-29818
83. Hanaka H., Shimizu T., and Izumi T. Nuclear-localization-dependent and nuclear-export-signal-dependent mechanisms determine the localization of 5-lipoxygenase. Biochem J 361 (2002) 505-514
84. Jones S.M., Luo M., Healy A.M., Peters-Golden M., and Brock T.G. Structural and functional criteria reveal a new nuclear import sequences on the 5-lipoxygenase protein. J Biol Chem 277 (2002) 38550-38556
85. Jones S.M., Luo M., Peters-Golden M., and Brock T.G. Identification of two novel nuclear import sequences on the 5-lipoxygenase protein. J Biol Chem 278 (2003) 10257-10263
86. Cipollone F., Mezzetti A., Fazia M.L., et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 25 (2005) 1665-1670
87. Mehrabian M., Wong J., Wang X., et al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 89 (2001) 125-130
88. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
89. Zhao L., Moos M.P., Grabner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973 [Epub August 22, 2004]
90. Kuhn H., Anton M., Gerth C., and Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol 1 (2003) 1
91. Shimizu T., Rådmark O., and Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA 81 (1984) 689-693
92. Toda A., Yokomizo T., and Shimizu T. Leukotriene B4 receptors. Prostaglandins other lipid Mediat 68-69 (2002) 575-585
93. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Freeman A., and Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
94. Bray M.A., Ford-Hutchinson A.W., and Smith M.J.H. Leukotriene B4: biosynthesis and biological activities. In: Piper P.J. (Ed). SRS-A and leukotrienes (1981), John Wiley & Sons Ltd. 253-270
95. Datta Y.H., Romano M., Jacobson B.C., Golan D.E., Serhan C.N., and Ewenstein B.M. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92 (1995) 3304-3311
96. Eriksson E.E., Xie X., Werr J., Thoren P., and Lindbom L. Importance of primary capture and l-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med 194 (2001) 205-218
97. Subbarao K., Jala V.R., Mathis S., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375 [Epub December 1, 2003]
98. 4 and BLT1 in smooth muscle cell recruitment. Circulation 112 (2005) 578-586
99. Back M., Bu D.X., Branstrom R., Sheikine Y., Yan Z.Q., and Hansson G.K. Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102 (2005) 17501-17506
100. Sheikine Y., and Hansson G.K. Chemokines and atherosclerosis. Ann Med 36 (2004) 98-118
101. Matsukawa A., Hogaboam C.M., Lukacs N.W., Lincoln P.M., Strieter R.M., and Kunkel S.L. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 163 (1999) 6148-6154
102. Huang L., Zhao A., Wong F., et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24 (2004) 1783-1788 [Epub July 22, 2004]
103. Lotzer K., Spanbroek R., Hildner M., et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 23 (2003) 32-36
104. Sjostrom M., Johansson A.S., Schroder O., Qiu H., Palmblad J., and Haeggstrom J.Z. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 271-276
105. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239 [Epub February 8, 2004]
106. Helgadottir A., Gretarsdottir S., St. Clair D., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
107. Lohmussaar E., Gschwendtner A., Mueller J.C., et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36 (2005) 731-736
108. Hakonarson H., Thorvaldsson S., Helgadottir A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256
109. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2005) 68-74
110. Funk C.D., Hoshiko S., Matsumoto T., Rådmark O., and Samuelsson B. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 86 (1989) 2587-2591
111. Hoshiko S., Rådmark O., and Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 87 (1990) 9073-9077
112. In K.H., Asano K., Beier D., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99 (1997) 1130-1137
113. Silverman E.S., Du J., De Sanctis G.T., et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 19 (1998) 316-323
114. Dishart D., Schnur N., Klan N., et al. GC-rich sequences in the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site. Biochim Biophys Acta 1738 (2005) 37-47
115. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
116. Drazen J.M., Yandava C.N., Dube L., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22 (1999) 168-170
117. Serhan C.N. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68-69 (2002) 433-455
118. Powell W.S., and Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 44 (2005) 154-183
119. Hatzelmann A., and Ullrich V. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem 169 (1987) 175-184